{
  "docId": "019de074-c89a-7228-80c7-3305707f7e50",
  "docSlug": "2a632d1edd5f737186449d0c40369511",
  "documentTitle": "AbCellera | Investor Presentation Deck | 20 slides",
  "authorId": "abcellera",
  "authorName": "AbCellera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 20,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "The slide uses a 4-column layout to explain the funding, its allocation, and the resulting strategic benefits.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-c89a-7228-80c7-3305707f7e50/16",
  "deckHref": "/decks/019de074-c89a-7228-80c7-3305707f7e50",
  "deckJsonHref": "/decks/019de074-c89a-7228-80c7-3305707f7e50.json",
  "deckAnchorHref": "/decks/019de074-c89a-7228-80c7-3305707f7e50#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.22,
        "x": 0.31,
        "y": 0.78
      },
      "kind": "chart",
      "text": "Project Investments: $224M Lab & Office, $193M Drug Candidate R&D, $102M Clinical Studies",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18906192-67c7-4f58-a0d4-043bc823b67b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.22,
        "x": 0.07,
        "y": 0.78
      },
      "kind": "chart",
      "text": "Funding Sources: $296M AbCellera, $167M Strategic Innovation Fund, $56M BC",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "927fd255-db35-4b61-ade5-2ee3b12bd8c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.22,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "list",
      "text": "Government co-investment is non-dilutive and provides certainty for accelerated strategy execution with high capital efficiency. Total $519 million co-investment. Government contribution is mix of 20% grant, 55% success-contingent, 25% repayable.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "224c652c-9179-43f4-8e20-1c9ceb32e1ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.22,
        "x": 0.31,
        "y": 0.25
      },
      "kind": "list",
      "text": "Investments will further strengthen leading engine to discover and develop antibody therapies. Accelerate build-out of fully-integrated capabilities. Leverage late-stage pre-clinical capability. Generate experience in taking programs into the clinic.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ff2d63b-a6fa-4d83-a22b-a27ed181a0ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.18,
        "x": 0.79,
        "y": 0.25
      },
      "kind": "list",
      "text": "AbCellera will be an even stronger company, propelling antibody-based medicines from target to clinic. Fully integrated target-to-patient capabilities. Track record established. Portfolio expanded. Liquidity runway extended.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf226b05-fb8b-470e-863d-f2b3b097590b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.22,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "list",
      "text": "Funding additional pre-partnered programs will enhance size and value of portfolio. Initiate up to 17 programs. Advance multiple programs through Phase 1. Strengthen program economics by adding value from target into clinic.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca5f432e-c72f-40a6-94a1-f9417445aefe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "AbCellera secures $222M (CA$300M) non-dilutive funding to accelerate execution of strategy and bring pre-partnered programs into clinic",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3eef40e7-b1d3-4a27-a4a3-948ea89c372f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "03112094-ca26-4a32-b40e-73fa646524ff",
      "evidence": "list/bullet: Investments will further strengthen leading engine to discover and develop antibody therapies.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}